Lilly's COVID-19 drug reduces death risk in patients on ventilator

Eli Lilly and Co. said new data from a Phase 3 trial showed its COVID-19 drug, baricitinib, was shown to reduce deaths in patients receiving mechanical ventilation.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.